Next Generation Cardiac Biomarker From Critical Diagnostics Accurately Predicts Risk of Heart Failure in the General Population

SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics, makers of the Presage® ST2 Assay, announced today that during a presentation at the American Heart Association Scientific Sessions in Los Angeles, the results of a study conducted through the Mayo Clinic and Foundation, Plasma Levels of ST2 in the Community: Association with cardiac remodeling, heart failure incidence and mortality, highlighted the remarkable accuracy of ST2 in predicting the risk of heart failure and mortality in the general population.

MORE ON THIS TOPIC